Véronique Paquis-Flucklinger

Prof. Dr. Véronique Paquis-Flucklinger

Department of Medical Genetics, Université Côte d'Azur, Nice Teaching Hospital (CHU de Nice), National Centre for Mitochondrial Diseases, Nice, France

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 March 2019 in Acta Neuropathologica
Verified
Journal Article
Closed access
PDF file
EGEmmanuelle C GENIN
Emmanuelle C GENIN
BHBlandine Madji Hounoum
Blandine Madji Hounoum
SBSylvie Bannwarth
Sylvie Bannwarth
KFKonstantina Fragaki
Konstantina Fragaki
SLSandra Lacas-Gervais
Sandra Lacas-Gervais
VPVéronique Paquis-Flucklinger
Véronique Paquis-Flucklinger

1 September 1997 in Genomics
Verified
Journal Article
Closed access
VPVéronique Paquis-Flucklinger
Véronique Paquis-Flucklinger
SSS. Santucci-Darmanin
S. Santucci-Darmanin
RPR. Paul
R. Paul
ASA. Saunières
A. Saunières
CTC. Turc-Carel
C. Turc-Carel
CDC. Desnuelle
C. Desnuelle

6 March 2017 in Human Molecular Genetics
Verified
Journal Article
Open access
PDF file
CRCécile Rouzier
Cécile Rouzier
DMDavid Moore
David Moore
CDCécile Delorme
Cécile Delorme
SLSandra Lacas-Gervais
Sandra Lacas-Gervais
SSSamira AIT EL MKADEM - SAADI
Samira AIT EL MKADEM - SAADI
VPVéronique Paquis-Flucklinger
Véronique Paquis-Flucklinger
Wolfram syndrome (WS) is a progressive neurodegenerative disease characterized by early-onset optic atrophy and diabetes mellitus, which can be associated with more extensive central nervous system and endocrine complications. The majority of patients harbour pathogenic WFS1 mutations, but recessive mutations in a second gene, CISD2, have been described in a small number of families with Wolfram syndrome type 2 (WFS2). The defining diagnostic criteria for WFS2 also consist of optic atrophy and diabetes mellitus, but unlike WFS1, this phenotypic subgroup has been associated with peptic ulcer disease and an increased bleeding tendency. Here, we report on a novel homozygous CISD2 mutation (c.215A > G; p.Asn72Ser) in a Moroccan patient with an overlapping phenotype suggesting that Wolfram syndrome type 1 and type 2 form a continuous clinical spectrum with genetic heterogeneity. The present study provides strong evidence that this particular CISD2 mutation disturbs cellular Ca2+ homeostasis with enhanced Ca2+ flux from the ER to mitochondria and cytosolic Ca2+ abnormalities in patient-derived fibroblasts. This Ca2+ dysregulation was associated with increased ER-mitochondria contact, a swollen ER lumen and a hyperfused mitochondrial network in the absence of overt ER stress. Although there was no marked alteration in mitochondrial bioenergetics under basal conditions, culture of patient-derived fibroblasts in glucose-free galactose medium revealed a respiratory chain defect in complexes I and II, and a trend towards decreased ATP levels. Our results provide important novel insight into the potential disease mechanisms underlying the neurodegenerative consequences of CISD2 mutations and the subsequent development of multisystemic disease.

10 May 2005 in Human Mutation
Verified
Journal Article
Closed access
PDF file
SBSylvie Bannwarth
Sylvie Bannwarth
VPVincent Procaccio
Vincent Procaccio
VPVéronique Paquis-Flucklinger
Véronique Paquis-Flucklinger
Molecular analysis of mitochondrial DNA (mtDNA) is a critical step in diagnosis and genetic counseling of respiratory chain defects. No fast method is currently available for the identification of unknown mtDNA point mutations. We have developed a new strategy based on complete mtDNA PCR amplification followed by digestion with a mismatch-specific DNA endonuclease, Surveyor™ Nuclease. This enzyme, a member of the CEL nuclease family of plant DNA endonucleases, cleaves double-strand DNA at any mismatch site including base substitutions and small insertions/deletions. After digestion, cleavage products are separated and analyzed by agarose gel electrophoresis. The size of the digestion products indicates the location of the mutation, which is then confirmed and characterized by sequencing. Although this method allows the analysis of 2 kb mtDNA amplicons and the detection of multiple mutations within the same fragment, it does not lead to the identification of homoplasmic base substitutions. Homoplasmic pathogenic mutations have been described. Nevertheless, most homoplasmic base substitutions are neutral polymorphisms while deleterious mutations are typically heteroplasmic. Here, we report that this method can be used to detect mtDNA mutations such as m.3243A>G tRNALeu and m.14709T>C tRNAGlu even when they are present at levels as low as 3% in DNA samples derived from patients with respiratory chain defects. Then, we tested five patients suffering from a mitochondrial respiratory chain defect and we identified a variant (m.16189T>C) in two of them, which was previously associated with susceptibility to diabetes and cardiomyopathy. In conclusion, this method can be effectively used to rapidly and completely screen the entire human mitochondrial genome for heteroplasmic mutations and in this context represents an important advance for the diagnosis of mitochondrial diseases. Hum Mutat 25:575–582, 2005.

16 December 2004 in Human Mutation
Verified
Journal Article
Open access
PDF file
FGFabienne Giuliano
Fabienne Giuliano
SBSylvie Bannwarth
Sylvie Bannwarth
SMSophie Monnot
Sophie Monnot
ACAline Cano
Aline Cano
BCBrigitte Chabrol
Brigitte Chabrol
VPVéronique Paquis-Flucklinger
Véronique Paquis-Flucklinger
Wolfram syndrome (WS), a rare autosomal recessive neurodegenerative disorder, results in most cases from mutations in the WFS1 gene. In this study, a total of 19 patients with Wolfram syndrome and 36 relatives from 17 families were screened for mutations in the WFS1 gene. WFS1 mutations were identified on both alleles in 16 of 19 patients and on 1 allele of 3 patients, showing that WFS1 is the major gene involved in WS in the french population. We identified 25 different mutations, twelve of which were novel. We found 6 frameshift mutations, 6 nonsense mutations, 6 missense mutations, 6 in‐frame deletions, and one new homozygous mutation in the splice donor site of exon 7 (c.861+1G>A) resulting in a frameshift. Most patients were compound heterozygotes. No common founder mutation or mutational hot spot were found in the WFS1 gene. Although most mutations occured in exon 8, in some cases molecular screening requires analysis of all exons, including the non‐coding exon 1. We also identified 3 new polymorphisms. Futhermore, genotype‐phenotype correlation suggests that the presence of inactivating mutations on both alleles may be associated with an early onset of diabetes mellitus.

30 November 2006 in Nature Protocols
Verified
Journal Article
Closed access
PDF file
SBSylvie Bannwarth
Sylvie Bannwarth
VPVincent Procaccio
Vincent Procaccio
VPVéronique Paquis-Flucklinger
Véronique Paquis-Flucklinger